Výsledky vyhledávání - "Michael T. Baratta"

Discovery and SAR of PF-4693627, a potent, selective and orally bioavailable mPGES-1 inhibitor for the potential treatment of inflammation

Autor: John Robert Springer, Gina M. Jerome, Hayes Michael J, Michael T. Baratta, Daniel P. Walker, Graciela B. Arhancet, Alexander F. Shaffer, Jaime L. Masferrer, Ben S. Zweifel, Steven E. Heasley, Darin E. Jones, William M. Moore, Jeffrey S. Carter, Yvette M. Fobian, Michael L. Vazquez, Sue Metz

Publikováno v: Bioorganic & Medicinal Chemistry Letters. 23:1114-1119

Inhibition of mPGES-1, the terminal enzyme in the arachidonic acid/COX pathway to regulate the production of pro-inflammatory prostaglandin PGE2, is considered an attractive new therapeutic target for safe and effective anti-inflammatory drugs. The d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b121fd58b89ecf308dd263c517c877ef
https://doi.org/10.1016/j.bmcl.2012.11.109

Zobrazit plný text záznamu

Synthesis and biological evaluation of substituted benzoxazoles as inhibitors of mPGES-1: Use of a conformation-based hypothesis to facilitate compound design

Autor: Daniel P. Walker, Alexander F. Shaffer, William M. Moore, Michael T. Baratta, Sue Metz, Jeffrey A. Scholten, John Robert Springer, Jeffrey S. Carter, Hwang-Fun Lu, Steven E. Heasley, Yvette M. Fobian, Natasha M. Kablaoui, Francisco M. Franco, Li Xing, Shengtian Yang, Hanau Cathleen E, Michael L. Vazquez, Graciela B. Arhancet, Gina M. Jerome

Publikováno v: Bioorganic & Medicinal Chemistry Letters. 23:1120-1126

Microsomal prostaglandin E(2) synthase-1 (mPGES-1) is a novel therapeutic target for the treatment of inflammation and pain. In the preceding letter, we detailed the discovery of clinical candidate PF-04693627, a potent mPGES-1 inhibitor possessing a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2d05bf0698be13f2291735a95c4465f
https://doi.org/10.1016/j.bmcl.2012.11.107

Zobrazit plný text záznamu

Accelerating drug development: methodology to support first-in-man pharmacokinetic studies by the use of drug candidate microdosing

Autor: Robert M. Ings, Christopher L Holliman, Gerald R. Galluppi, Matthew A. McLean, Chi-Yan J. Tam, Michael T. Baratta

Publikováno v: Drug Development Research. 68:14-22

Microdosing of experimental therapeutics in humans offers a number of benefits to the drug development process. Microdosing, conducted under an exploratory Investigational New Drug (IND) application, entails administration of a sub-pharmacological do

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dedd03534dd4ac0d6af9d7a41078b2c2
https://doi.org/10.1002/ddr.20160

Zobrazit plný text záznamu

Abstract 4540: Preclinical pharmacology and antitumor activity of CP-744809, a highly selective orally available small molecule inhibitor of aldose reductase

Autor: David W. Griggs, David A. Matulewic, Michael T. Baratta, Kristen E. Shannon, Scott D. Hauser, Pegg Jodi Ann

Publikováno v: Cancer Research. 70:4540-4540

Aldose reductase (AKR1B1) mediates the first and rate limiting step in the conversion of glucose to polyols that contribute to redox imbalance, formation of reactive oxygen species, and activation of signal transduction pathways that can promote tumo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fbe6f7fb8c98f7f9f839f70a4d6460cd
https://doi.org/10.1158/1538-7445.am10-4540

Zobrazit plný text záznamu

Akademický článek

Accelerating drug development: methodology to support first‐in‐man pharmacokinetic studies by the use of drug candidate microdosing.

Autor: Matthew A. McLean, Chi‐Yan J. Tam, Michael T. Baratta, Christopher L. Holliman, Robert M. Ings, Gerald R. Galluppi

Publikováno v: Drug Development Research; Feb2007, Vol. 68 Issue 1, p14-22, 9p

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání